TGFBI has been proved to be related with paclitaxel-resistance in ovarian cancer, which might be a potential therapeutic target for the enhancement of responses to chemotherapy in ovarian cancer patients (Wang et al., 2012). This evidence concerns the gene TGFBI and ovarian carcinoma.